New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A 3 adenosine receptor antagonists

Journal of Medicinal Chemistry

Volumn 48, Issue 15, 2005, Pages 5001-5008

  Baraldi, Pier Giovanni ^a   Tabrizi, Mojgan Aghazadeh ^a   Preti, Delia ^a   Bovero, Andrea ^a   Fruttarolo, Francesca ^a   Romagnoli, Romeo ^a   Zaid, Naser Abdel ^b   Moorman, Allan R ^c   Varani, Katia ^a   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b AN NAJAH NATIONAL UNIVERSITY   (Palestine)

^c King Pharmaceutical R and D   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYL 2,5 DIHYDROPYRAZOLO[4,3 C]QUINOLIN 4 ONE DERIVATIVE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; PHENYL GROUP; PYRAZOLONE DERIVATIVE; QUINOLINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; EVALUATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIRA VILSMEIER REACTION; LIGAND BINDING; NONHUMAN; RADIOASSAY; RAT; RECEPTOR AFFINITY; SUBSTITUTION REACTION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; HUMANS; PYRAZOLES; QUINOLINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, ADENOSINE A3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 22744459340     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050125k     Document Type: Article

References (40)

1. Fredhol, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552.
2. 2 purine and pyrimidine receptor ligands. In: Purinergic and Pyrimidinergic Signaling; Abbracchio, M. P., Williams, M., Eds.; Handbook of Experimental Pharmacology, Vol 151/1; Springer: Berlin. 2001, 129-175.
3. Poulsen, S. A.; Quinn, R. J. Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. 1998, 6, 619-641.
4. 3 adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10365-9.
5. 3 receptors is associated with enhancement of antigen- and Ca(2+)-ionophore-induced secretion in a rat mast cell line. J. Pharmacol. Exp. Ther. 1996, 276, 837-45.
6. Murphree, L. J.; Linden, J. Adenosine Receptors. Encyclopedia of Biological Chemistry 2004, 1, 34-39.
7. Fredholm, B. B. Adenosine receptors as targets for drug development. Drug News & Perspectives 2003, 16 (5), 283-289.
8. 3 adenosine receptor affects cell cycle progression and cell growth. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 225-34.
9. Van Schaick, E. A.; Jacobson, K. A.; Kim, H. O.; IJzerman, A. P.; Danhof, M. Haemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonists 2-Cl-IB-MECA in conscious rats. Eur. J. Pharm. 1996, 308, 311-314.
10. 3 receptor stimulation on seizures in mice. Eur. J. Pharmacol. 1995, 275, 23-29.
11. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 1994, 263, 59-67.
12. 3 receptor. Cancer Res. 1994, 54, 3521-3526.
13. 3 receptor-N6-2-(4-aminophenyl)ethyladenosine induces bronchospasm in BDE rats by a neurally mediated mechanism involving cells resembling mast cells. J. Pharmacol. Exp. Ther. 1996, 279, 1148-1156.
14. Forsythe, P.; Ennis, M. Adenosine, mast cells and asthma. Inflamm. Res. 1999, 48, 301-307.
15. Jacobson, K. A.; Tchilibon, S. J.; Bhalchandra, V.; Gao, Z.-G. A3 Adenosine Receptors. Annual Reports in Medicinal Chemistry 2003, 38, 121-130.
16. 3 receptors: Neuroprotective targets with perspectives. Bioforum 2002, 25 (4), 237-240.
17. 2a adenosine binding activity. Eur. J. Med. Chem. 1995, 30, 133-139.
18. 2A adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-ones, 1-aryl- 4,9-dihydro-3-methyl-1H-pyrazolo[3,4-6]quinolin-4-ones, and 1-aryl-1H-imidazo[4, 5-6]quinoxalines. J. Med. Chem. 1995, 38, 1330-1336.
19. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. 4-Amino-6-benzyl-amino-1,2-dihydro- 2-phenyl-1,2,4-triazolo[4,3a] quinoxalin-1-one: a new A2A adenosine receptor antagonist with high selectivity versus A1 receptors. Arch. Pharm. (Weinheim, Ger. 1999, 332, 39-41.
20. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. J. Med. Chem. 2000, 43, 3118-3124.
21. 3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modelling studies. J. Med. Chem. 2004, 47, 3580-3590.
22. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. 1,2,4-Triazolo[4,3-a]-quinoxalin-1- one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. J. Med. Chem. 2000, 43, 1158-1164.
23. Colotta, V.; Catarzi, D.; Varano, F.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. Synthesis and structure-activity relationships of a new set of 1,2,4-Triazolo[4,3-a]quinoxalin-1-one Derivatives as Adenosine Receptor Antagonists. Bioorg. Med. Chem. 2003, 11, 3541-3550.
24. 3 Adenosine Receptor Antagonists. Drug Dev. Res. 2003, 58, 315-329.
25. 3 Adenosine Receptor Antagonists. J. Med. Chem. 1999, 42, 4473-4478.
26. 3 Adenosine Receptor Antagonists: Influence of the Chain at the N8 Pyrazole Nitrogen. J. Med. Chem. 2000, 43, 4768-4780.
27. Baraldi, P. G.; Cacciari, B.; Moro, S.; Romagnoli, R.; Ji, X. D.; Jacobson, K. A.; Gessi, S.; Borea, P. A.; Spalluto, G. Fluorosulfonyl- and Bis-(β-chloroethyl)amino-phenylamino Functionalized Pyrazolo[4,3-e]1,2,4- triazolo[1,5-c]pyrimidine Derivatives: Irreversible Antagonists at the Human AS Adenosine Receptor and Molecular Modelling Studies. J. Med. Chem. 2001, 44, 2735-2742.
28. 3 Adenosine Receptor Antagonists. J. Med. Chem. 2001, 45, 770-780.
29. Werbel, L. M.; Kesten, S. J.; Turner, W. R. Structure-activity relationship of antimalarial indolo[3,2-c]qiunolines[1,2]. Eur. J. Med. Chem. 1993, 28, 837-852.
30. Sangwan, N. K.; Kelkar, K.; Prabhakar, M.; Rastogi, S. N.; Anand, N. Antifertility agents: Part XLIII. Synthesis of 3-aryl-4,5-dihydro-2-substituted- 5-tosyl-2H-pyrazolo[4,3-c]quinolines and 2,4-dihydro-3-phenyl[1]benzopyrano[4,3- c]pyrazoles and their derivatives. Indian journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry 1985, 24B (6), 639-44.
31. Baraldi, P. G.; Manfredini, S.; Periotto, V.; Simoni, D.; Guarneri, M.; Borea, P. A. Synthesis and Interaction of 5-(Substituted-phenyl)-3-methyl-6,7- dihydropyrazolo[4,3-e][1,4]diazepin-8(7H)-ones with Benzodiazepine Receptors in Rat Cerebral Cortex. J. Med. Chem. 1985, 28, 683-685.
32. Xu, Y.-C.; Schaus, J. M.; Walker, C.; Krushinski, J.; Adham, N.; Zgombick, J. M.; Liang, S. X.; Kohlman, D. T.; Audia, J. E. N-Methyl-5-tert- butyltryptamine: A Novel, Highly Potent 5-HT1D Receptor Agonist. J. Med. Chem. 1999, 42, 526-531.
33. Klotz, K. N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedeberg's Arch Pharmacol. 1998, 357, 1-9.
34. 2A adenosine receptors. Life Sciences 1996, 59, 1373-1388.
35. 2A receptor ligands. Biochem. Pharmacol. 1995, 49, 461-469.
36. 3 adenosine receptors. Mol. Pharmacol. 2000, 57, 968-975.
37. 3 adenosine receptors. Life Sciences 1998, 63, 81-87.
38. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 7, 248-54.
39. i) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 1, 3099-108.
40. Munson, P. J.; Rodbard, D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 1980, 107, 220-39.